Regulating Cell Therapies: Conditional Approval Under Consideration In Congress; FDA Plans Public Hearing
This article was originally published in RPM Report
Does FDA need a new pathway to consider advances in cellular therapy? Some in Congress think so. FDA is inviting stakeholders to weigh in this fall.
Register for our free email digests: